FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

研究/FDA Proposes Excluding Semaglutide and Other Peptides from Clinical Need List
返回研究图书馆

FDA Proposes Excluding Semaglutide and Other Peptides from Clinical Need List

May 25, 2026
Share
新兴研究

基于新兴研究。这些发现很有前景,但需要进一步验证。

关于此分析

本文是基于最近发布的新闻或临床试验公告的人工智能辅助摘要。旨在为肽类研究社区提供快速、易懂的概览。欲获得完整准确性,请参阅下方提供的原始来源。

FDA Proposes Excluding Semaglutide and Other Peptides from Clinical Need List

In a recent notice published in the Federal Register, the Food and Drug Administration (FDA) has proposed excluding several peptides, including semaglutide and liraglutide, from the list of bulk drug substances for which there is a clinical need under Section 503B of the Federal Food, Drug, and Cosmetic Act. This decision could impact how these medications are compounded in outsourcing facilities.

Background

The FDA regularly reviews nominations for inclusion on its 503B Bulks List to ensure that active pharmaceutical ingredients (APIs) with significant clinical demand can be used by outsourcing facilities without violating federal regulations. Outsourcing facilities, under Section 503B of the FDCA, are allowed to compound sterile preparations and non-sterile preparations if they meet specific requirements set forth by the FDA.

The process involves evaluating substances based on their clinical need, safety, and efficacy in treating various conditions. The FDA considers nominations for inclusion or exclusion after reviewing public comments and scientific data submitted by stakeholders. This recent announcement highlights a significant shift in how certain peptides are viewed within the regulatory framework.

Key Details

According to the notice published on May 1, 2026, the FDA has identified three bulk drug substances—semaglutide, tirzepatide, and liraglutide—as those that will not be included on the 503B Bulks List. These peptides are widely used in treating type 2 diabetes and obesity due to their effectiveness in lowering blood sugar levels and promoting weight loss.

The FDA's decision is based on several factors, including existing market availability of these drugs through conventional manufacturing processes. The agency also considered safety data indicating that compounding these substances might not be feasible or advisable without additional regulatory oversight.

Other bulk drug substances nominated for inclusion are still under consideration, with the possibility of future updates from the FDA regarding their status on the list.

Key Takeaways

  • Semaglutide and Liraglutide Excluded: The FDA has proposed excluding semaglutide and liraglutide from the 503B Bulks List.
  • No Immediate Impact on Availability: This decision does not mean these drugs will become less accessible; they remain available through conventional manufacturing processes.
  • Regulatory Oversight: Compounding of excluded peptides may face stricter regulations or be prohibited entirely in certain circumstances.
  • Potential for Future Updates: The FDA is still reviewing other substances and future updates could impact the list.

What This Means

For peptide researchers, clinicians, and informed consumers, this development underscores the importance of understanding regulatory frameworks governing compounded medications. While the exclusion of semaglutide, tirzepatide, and liraglutide may limit their availability through compounding facilities, these drugs remain accessible through traditional pharmaceutical manufacturing.

The FDA's decision highlights the need for continued dialogue between regulatory bodies, healthcare providers, and researchers to ensure that patients have access to safe and effective treatments. Peptide therapy remains a crucial area of research and clinical application, and stakeholders should stay informed about updates to regulatory guidelines affecting compounded medications.

---

Source: Federal Register — Published 2026-05-01

This article is for informational purposes only and does not constitute medical advice.

编辑注释

此分析使用人工智能工具生成,并由Peptide Contacts编辑团队审核。尽管我们力求准确,但人工智能生成的内容可能包含错误或遗漏。鼓励读者查阅 原始来源 以获取完整细节、方法和数据。

Peptide Contacts提供研究摘要仅供信息参考之用。此内容不构成医疗建议。在做出任何健康决策前,请咨询合格的医疗服务提供者。

Comments

Sign in to join the discussion

本文由人工智能生成,可能存在不准确之处。仅供信息参考之用,并不构成医疗建议。请务必通过原始来源核实信息并在做出任何健康决策前咨询合格的医疗服务提供者。